• Optimizing Fusion Tag Cleavage: PreScission Protease (PSP) i

  2026-05-03

  This article delivers scenario-driven guidance for using PreScission Protease (PSP) (SKU K1101) in sensitive protein purification workflows. Drawing on validated protocols and peer-reviewed data, it addresses real-world challenges faced by biomedical researchers—emphasizing reproducibility, tag cleavage precision, and workflow compatibility.

• Elobixibat Hydrate: Transforming IBAT Inhibition Workflows

  2026-05-02

  Elobixibat hydrate, a selective ileal bile acid transporter inhibitor, is redefining research and clinical protocols for chronic idiopathic constipation and metabolic modulation. This article details actionable, experiment-ready workflows and troubleshooting strategies, equipping teams to maximize efficacy and reproducibility with APExBIO's validated reagent.

• PKH26 Red Fluorescent Cell Linker Kit: Technical Use Guidanc

  2026-05-01

  The PKH26 Red Fluorescent Cell Linker Kit provides researchers with a robust tool for labeling cell membrane lipid regions, supporting long-term tracking of cells in both in vitro and in vivo studies. It is not suitable for labeling intracellular targets or for applications outside the membrane lipid domain, ensuring specificity and signal stability for cell tracing and proliferation analysis.

• TG003 Cdc2-like Kinase Inhibitor: Splicing Modulation in Act

  2026-05-01

  TG003, a highly selective Cdc2-like kinase inhibitor, delivers nanomolar precision for dissecting alternative splicing and overcoming platinum resistance in cancer models. Its robust workflow compatibility and evidence-backed performance make it indispensable for splice site selection research and therapeutic strategy development.

• Vincristine Sulfate: Mechanistic Precision for Translational

  2026-04-30

  This thought-leadership article examines the mechanistic underpinnings and strategic deployment of vincristine sulfate in translational cancer research. By integrating mechanistic insight, validated protocol parameters, and cross-study synthesis—including evidence from anti-inflammatory drug repositioning—we provide actionable guidance for researchers advancing therapies in acute lymphoblastic leukemia, non-Hodgkin lymphoma, and beyond. The narrative differentiates itself by bridging microtubule disruption with systems-level workflow optimization, leveraging APExBIO’s Vincristine sulfate as a data-driven benchmark.

• Metabolomics Identifies Biomarkers of Carbapenem Resistance

  2026-04-30

  This study leverages LC-MS/MS metabolomics to rapidly distinguish carbapenemase-producing Enterobacterales (CPE) from non-CPE isolates using metabolite biomarkers. The findings have significant implications for advancing antibiotic resistance studies and diagnostic assay development.

• Host-Directed Therapy: GSK3 Inhibition in Tuberculosis Contr

  2026-04-29

  This study uncovers glycogen synthase kinase 3 (GSK3) inhibition as a viable host-directed therapy for controlling Mycobacterium tuberculosis (Mtb) infection. By leveraging kinase inhibitors, the research demonstrates effective suppression of intracellular Mtb growth and highlights new avenues for non-antibiotic intervention in tuberculosis.

• Nicotinamide Adenine Dinucleotide: Applied Workflows & Troub

  2026-04-29

  Nicotinamide Adenine Dinucleotide (NAD+) from APExBIO is central to advanced metabolic signaling and autophagy research, offering precise control in enzymatic and stress-response workflows. This guide delivers stepwise protocols, troubleshooting insights, and actionable interpretation of recent AMPK–autophagy breakthroughs to optimize your assays.

• Tamoxifen in Research: SERM-Driven Innovation & Protocol Mas

  2026-04-28

  Tamoxifen, a benchmark selective estrogen receptor modulator, powers reliable gene knockout and cancer biology models while enabling advanced kinase and antiviral assays. This guide delivers actionable workflows, troubleshooting insights, and highlights a cutting-edge CARM1-targeted approach to overcoming endocrine resistance.

• Angiotensin 1/2 (1-6): Applied Use-Cases in Cardiovascular &

  2026-04-28

  Angiotensin 1/2 (1-6) empowers researchers to dissect vascular tone regulation and investigate viral-host interactions with remarkable precision. Its validated use in both cardiovascular and emerging SARS-CoV-2 research opens new avenues for translational discovery. Explore advanced workflow optimizations, troubleshooting strategies, and evidence-based protocol enhancements below.

• Topotecan as First-Line Therapy for Small Cell Lung Cancer:

  2026-04-27

  This article analyzes the reference study's evaluation of topotecan in first-line treatment regimens for small cell lung cancer (SCLC), emphasizing its mechanistic novelty and manageable toxicity profile. Key findings are contextualized with current paradigms in topoisomerase inhibitor research and compared with insights from Irinotecan-focused studies in colorectal cancer models.

• Cy5 Maleimide (Non-sulfonated): Precision in Translational P

  2026-04-27

  Explore how Cy5 maleimide (non-sulfonated) unlocks site-specific protein labeling for next-generation translational research, with a focus on mechanistic insights, experimental strategies, and clinical impact. This article connects the latest findings in biomolecular condensate biology with actionable guidance for leveraging thiol-reactive fluorescent probes in precision workflows.

• Tropifexor (LJN452): Advanced FXR Modulation for Translation

  2026-04-26

  This article explores Tropifexor (LJN452) as a next-generation FXR agonist, synthesizing mechanistic insights and strategic recommendations for translational researchers. We contextualize its use in metabolic and liver disease models, highlight protocol best practices, and position APExBIO’s offering within the competitive landscape. By bridging foundational biology with actionable guidance, we chart new territory beyond conventional product summaries.

• Topotecan and Etoposide: Innovations in Topoisomerase Inhibi

  2026-04-25

  This article reviews the seminal work on topotecan, a topoisomerase I inhibitor, highlighting its mechanism, pharmacokinetics, and clinical impact. It contextualizes the findings alongside established topoisomerase II inhibitors such as Etoposide (VP-16), emphasizing the implications for DNA damage assays and cancer chemotherapy research.

• USP7-PKM2 Axis Governs Macrophage Polarization in Acute Panc

  2026-04-24

  This study uncovers how ubiquitin-specific protease 7 (USP7) modulates macrophage polarization and inflammation in severe acute pancreatitis (SAP) via PKM2-dependent metabolic reprogramming. The findings highlight PKM2 as a pivotal metabolic checkpoint in immune regulation and offer a mechanistic rationale for investigating PKM2 inhibitors in inflammatory disease models.

15601 records 1/1041 page Next 12345 下5页 Last page